BioMark Diagnostics (20B) Stock Price & Analysis

20B Stock Chart & Stats

€0.27€0.00(0.00%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 0.26 - EUR 0.27
52-Week Range: EUR 0.17 - EUR 0.42
Previous Close: EUR 0.27
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 32.07M
Enterprise Value: EUR 58.98M
Total Cash (Recent Filing): EUR 788.32K
Total Debt (Recent Filing): EUR 1.27M
Price to Earnings (P/E): ―
Beta: 0.20
Next Earnings: Nov 27, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Early-detection Diagnostics Focus

A focused position in blood-based biomarker testing and early disease detection gives BioMark a clearly defined diagnostic mission. If clinical validation progresses, this specialization could support differentiated applications in screening and monitoring rather than relying on a broad, unfocused product strategy.

Equity Position Recovered

The return to positive equity in FY2025 and the TTM period is a meaningful improvement from the earlier negative-equity years. Although leverage remains a concern, restored positive net assets provide a stronger accounting foundation and may improve financial flexibility compared with the prior balance-sheet position.

Positive EPS Growth Metric

The reported positive EPS growth metric indicates improvement in per-share earnings performance relative to the comparison period, even though the company remains loss-making overall. If sustained alongside revenue recovery and better margins, this could become an early indicator of improving earnings quality over subsequent periods.

Bears Say

Sharp Revenue Contraction

The steep decline in revenue shows that the business has not yet established durable commercial momentum. A shrinking top line limits operating leverage, reduces resources available for diagnostic development, and makes it harder for fixed costs to be absorbed as the company pursues clinical validation.

Persistent Unprofitable Operations

Negative gross profit and large operating losses indicate that current activities are not covering direct costs or operating expenses. Persistent losses weaken internal funding capacity and leave the company dependent on future commercial improvement or external capital to advance its diagnostic programs.

Cash Burn And Elevated Leverage

Consistent operating and free-cash-flow deficits show that BioMark is not self-funding, while debt above twice equity increases financing pressure. Together, cash burn and leverage can constrain investment in development, heighten reliance on external funding, and raise dilution or refinancing risk.

BioMark Diagnostics News

BioMark to Spotlight Metabolomics Platform at Quebec Life Sciences Conferences

BioMark Diagnostics ( ($TSE:BUX) ) has provided an announcement. BioMark Diagnostics will participate in the MSACL 2026 and BIOHorizon 2026 conferences in Quebec in early October, engaging clinical mass spectrometry

1M ago20B BUX

BioMark Wins Global Scientific Backing for AI-Driven Lung Cancer Blood Test

The latest update is out from BioMark Diagnostics ( ($TSE:BUX) ). BioMark Diagnostics has reported significant scientific momentum for its metabolomics-based liquid biopsy platform for early lung cancer detection, with

2M ago20B BUX

BioMark to Showcase Home-Based Lung Cancer Blood Test at Canadian Thoracic Forum

BioMark Diagnostics ( ($TSE:BUX) ) just unveiled an update. BioMark Diagnostics Inc., a Canadian developer of liquid biopsy cancer tests powered by metabolomics and machine learning, is advancing blood-based tools

6M ago20B BUX

BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics ( ($TSE:BUX) ) has provided an update. BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication

9M ago20B BUX

BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication

9M ago20B BUX

BioMark Leverages Landmark Lung Cancer Studies and New Funding to Drive 2026 Expansion

BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics reported a transformative 2025 marked by major capacity expansion, clinical validation and growing industry recognition, as it doubled laboratory

10M ago20B BUX

BioMark Adds AI-Focused Investor James Lavender to Board to Drive U.S. Expansion

BioMark Diagnostics ( ($TSE:BUX) ) has issued an update. BioMark Diagnostics has appointed technology investor and AI-focused growth strategist James Lavender to its board of directors following approval at the

10M ago20B BUX

BioMark Launches ISO 15189 Accreditation Drive to Accelerate Global Commercialization

An update from BioMark Diagnostics ( ($TSE:BUX) ) is now available. BioMark Diagnostics Inc. has begun the process to obtain ISO 15189 accreditation for its medical laboratory in Quebec City

10M ago20B BUX

BioMark Diagnostics Wins Innovation Award for Lung Cancer Screening Project

BioMark Diagnostics ( ($TSE:BUX) ) has provided an announcement. BioMark Diagnostics Inc. and its research partners have been honored with the Innovation Award at the ADRIQ Innovation Awards Gala for

11M ago20B BUX

BioMark Supports National Plan to Slash Lung Cancer Mortality

BioMark Diagnostics ( ($TSE:BUX) ) has provided an update. BioMark Diagnostics Inc. is aligning with the Canadian Cancer Society’s 2026-2035 Pan-Canadian Lung Cancer Action Plan to reduce lung cancer mortality

11M ago20B BUX

20B FAQ

What was BioMark Diagnostics’s price range in the past 12 months?

BioMark Diagnostics lowest stock price was €0.17 and its highest was €0.42 in the past 12 months.

What is BioMark Diagnostics’s market cap?

BioMark Diagnostics’s market cap is €32.07M.

When is BioMark Diagnostics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were BioMark Diagnostics’s earnings last quarter?

BioMark Diagnostics released its earnings results on Jul 29, 2026. The company reported -€0.002 earnings per share for the quarter.

Is BioMark Diagnostics overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does BioMark Diagnostics pay dividends?

BioMark Diagnostics does not currently pay dividends.

What is BioMark Diagnostics’s EPS estimate?

BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BioMark Diagnostics have?

BioMark Diagnostics has 106,483,440 shares outstanding.

What happened to BioMark Diagnostics’s price movement after its last earnings report?

BioMark Diagnostics reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went up 0.709%.

Which hedge fund is a major shareholder of BioMark Diagnostics?

Currently, no hedge funds are holding shares in DE:20B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description